Piramal Pharma Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,617 Cr +28.1% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
PP

Piramal Pharma Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Piramal Pharma Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹2,140Cr
−2.9% YoY
+4.7% QoQ
Net profit
−₹136Cr
Q3 FY25: ₹4 Cr
Margin
9.15%
−6.2 pp YoY
+1.4 pp QoQ
Price₹214
Market cap₹27.5K Cr

The short version

Q4 is expected to show sequential revenue growth compared to Q3, but no year-on-year Q4 versus Q4 growth due to a strong large order last year. FY '26 is muted due to inventory destocking, slower U.S.

From Piramal Pharma Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Q4 is expected to show sequential revenue growth compared to Q3, but no year-on-year Q4 versus Q4 growth due to a strong large order last year.
  • CDMO business (excluding inventory destocking) is growing in low single digits, with expectations for continued growth driven by improved biotech funding and new client additions.
  • Overseas CDMO facilities with high gross margin profiles are anticipated to enhance margins as capacity utilization improves.
  • The consumer products business, now breakeven, is expected to expand margins and grow further.
  • The Kenalog acquisition (annualized sales $30-$40 million) adds a stable, near-to-medium-term contributor, fitting strategically with existing portfolio and sales capabilities.

2 more points from Piramal Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Piramal Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Average CAPEX spend is between $70 million to $100 million annually.
  • Higher CAPEX expected in the near term due to major expansions at Lexington and Riverview facilities.
  • Lexington expansion is underway, with commissioning expected by end of Calendar Year 2027.
  • Riverview facility's linker payload expansion is nearly ready and expected to come online this quarter.
  • Investments are aligned with long-term plans and payback metrics for CDMO and Complex Hospital Generics (CHG) businesses.
  • Consumer products business is self-funding and does not require external capital infusion.

2 more points from Piramal Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Piramal Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company has a large Phase-3 pipeline with over 30 products, with programs primarily in oncology, metabolic diseases, and rare diseases.
  • Order booking saw an improvement in Q3 FY '26, serving as a leading indicator of client ability to fund and spend on CDMO services.
  • Since October 2025, there has been a significant increase in RFPs (Request for Proposals), especially for U.S. facilities, indicating growing demand.
  • Typical lead time from proposal to client decision is around 180 days.
  • There is cautious optimism about translating these RFPs into confirmed orders over the next 180 days.
  • The impact of inventory destocking on order volumes is expected to normalize, with underlying portfolio growth in low single digits excluding destocking effects.

2 more points from Piramal Pharma Ltd's call on order book

Create a free account to keep reading this call

Piramal Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Piramal Pharma Ltd Q3 FY26 results — key figures

Piramal Pharma Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue2,1402,204-2.9%2,044+4.7%
Operating profit (EBITDA)196338-42%159+23.3%
Operating margin9.15%15.32%-6.2 pp7.76%+1.4 pp
Profit before tax-9467-240.5%-46—
Net profit (PAT)-1364-3800.8%-99—
EPS (₹)-1.020.03-3500%-0.75—

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.6K Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Piramal Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Piramal Pharma Ltd Q3 FY26 results?

Q4 is expected to show sequential revenue growth compared to Q3, but no year-on-year Q4 versus Q4 growth due to a strong large order last year. FY '26 is muted due to inventory destocking, slower U.S.

What is Piramal Pharma Ltd share price analysis?

Piramal Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹27,530 Cr. Investors should review the full earnings analysis for detailed insights.

Is Piramal Pharma Ltd planning capital expenditure?

Average CAPEX spend is between $70 million to $100 million annually.

Keep Piramal Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.